Chemotherapy options and outcomes in older adult patients with colorectal cancer

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 2, 2009, Pages 155-169

  Saif, Muhammad W ^a   Lichtman, Stuart M ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Aging; Chemotherapy; Colorectal cancer; Older adult; Toxicity

Indexed keywords

ANTICOAGULANT AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; IRINOTECAN; OXALIPLATIN; PANITUMUMAB; QUINAPRIL; TEGAFUR; VASCULOTROPIN INHIBITOR; WARFARIN;

ACUTE PSYCHOSIS; ADJUVANT THERAPY; ADVANCED CANCER; AGED; AGING; ANEMIA; ASTHENIA; BIOLOGICAL THERAPY; BOLUS INJECTION; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CARDIOTOXICITY; CLINICAL TRIAL; COLORECTAL CANCER; COMORBIDITY; CONTINUOUS INFUSION; DEHYDRATION; DETOXIFICATION; DIARRHEA; DRUG ANTAGONISM; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TARGETING; DRUG WITHDRAWAL; FATIGUE; FEBRILE NEUTROPENIA; FRAIL ELDERLY; FUNCTIONAL STATUS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; GERIATRIC ASSESSMENT; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INFECTION; LETHARGY; LEUKOPENIA; LIVER METASTASIS; LIVER RESECTION; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL NEUROPATHY; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; RISK BENEFIT ANALYSIS; SENSORY DYSFUNCTION; SENSORY NEUROPATHY; SKIN TOXICITY; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGE FACTORS; AGED; AGING; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COLORECTAL NEOPLASMS; HUMANS; TREATMENT OUTCOME;

EID: 71749084894     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.02.006     Document Type: Review

References (78)

1. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2004, National Cancer Institute. Bethesda, MD. Table I-1: Estimated new cancer cases and deaths for 2007. Data submitted to SEER website 2007. Available at http://seer.cancer.gov/csr/1975_2004/; accessed November 15, 2007.
2. Muss H. Older age-not a barrier to cancer treatment. N Engl J Med 345 (2001) 1128-1129
3. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2004, National Cancer Institute. Bethesda, MD. Table I-10: Age distribution (%) of incidence cases by site, 2000-2004. Data submitted to SEER website 2007. Available at http://seer.cancer.gov/csr/1975_2004/; accessed March 25, 2008.
4. Sargent D., Goldberg R., Jacobson S., et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in older patients. N Engl J Med 345 (2001) 1091-1097
5. Yancik R. Population aging and cancer: a cross-national concern. Cancer 11 (2005) 437-441
6. Ries L, Melbert D, Krapcho M, et al. SEER Cancer Statistics Review 1975-2004. National Cancer Institute. Bethesda, MD. Table I-11: Median age of cancer patients at diagnosis, 2000-2004 by primary cancer site, race and sex. Data submitted to SEER website 2007. Available at http://seer.cancer.gov/csr/1975_2004/; accessed March 5, 2008.
7. Goldman D., Lewis J.L., Kilgore M.L., et al. The participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 21 (2003) 1383-1389
8. Potosky A., Harlan L., Kaplan R., et al. Age, sex, and racial differences in the use of standard adjuvant therapy for colorectal cancer. J Clin Oncol 20 (2002) 1192-1202
9. Ho C., O'Reilly S., Ng K., et al. Population-based analysis of patients with advanced colorectal cancer: the impact of age on treatment and outcomes. J Clin Oncol 23 16S (2005) [abstract 3614]
10. National Center for Health Statistics. Health, United States, 2006. Available at http://www.cdc.gov/nchs/data/hus/hus06.pdf; accessed March 25, 2008.
11. Sargent D., Wieand S., Benedetti J., et al. Disease-free survival (DFS) vs. OS (OS) as a primary endpoint for adjuvant colon cancer studies: individual patient data from 12,915 patients on 15 randomized trials. J Clin Oncol 23 14S (2004) [abstract 3502]
12. Sanoff H.K., Bleiberg H., and Goldberg R.M. Managing older patients with colorectal cancer. J Clin Oncol 25 (2007) 1891-1897
13. Kelly H., and Goldberg R. Systemic therapy for metastatic colorectal cancer: Current options, current evidence. J Clin Oncol 23 (2005) 4553-4560
14. Gross C., McAvay G., Krumholz H., et al. The effect of age and chronic illness on life expectancy after a diagnosis of colorectal cancer: implications for screening. Ann Intern Med 145 (2006) 646-653
15. Sawhney R., Sehl M., and Naeim A. Physiologic aspects of aging: Impact on cancer management and decision making, part I. Cancer J 11 (2005) 449-460
16. Sehl M., Sawhney R., and Naeim A. Physiologic aspects of aging: Impact on cancer management and decision making, part II. Cancer J 11 (2005) 461-473
17. Lichtman S.M., and Villani G. Chemotherapy in the elderly: pharmacologic considerations. Cancer Control 7 (2000) 548-556
18. Wedding U., Honecker F., Bokemeyer C., et al. Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14 (2007) 44-56
19. Ferrucci L., Guralnik J.M., Cavazzini C., et al. The frailty syndrome: a critical issue in geriatric oncology. Crit Rev Oncol Hematol 46 (2003) 127-137
20. Walston J., Hadley E., Ferrucci L., et al. Research agenda for frailty in older adults: toward a better understanding of physiology and etiology-summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 54 (2006) 991-1001
21. Wolfson C., Wolfson D.B., Asgharian M., et al. A reevaluation of the duration of survival after the onset of dementia. N Engl J Med 344 (2001) 1111-1116
22. Lichtman S.M. Therapy insight: therapeutic challenges in the treatment of elderly cancer patients. Nat Clin Pract Oncol 3 (2006) 86-93
23. Jansen C.E., Miaskowski C., Dodd M., et al. A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function. Cancer 104 (2005) 2222-2233
24. Bailey C., Corner J., Addington-Hall J., et al. Treatment decisions in older patients with colorectal cancer: the role of age and multidimensional function. Eur J Cancer Care (Engl) 12 (2003) 257-262
25. Lemmens V., van Halteren A., Janssen-Heijnen M., et al. Adjuvant treatment for elderly patients with stage III colon cancer in southern Netherlands is affected by socioeconomic status, gender, and comorbidity. Ann Oncol 16 (2005) 767-772
26. Bandeen-Roche K., Xue Q.L., Ferrucci L., et al. Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci 61 (2006) 262-266
27. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Senior Adult Oncology, vol. 2; 2007.
28. Daniele B., Rosati G., Tambaro R., et al. First-line chemotherapy with fluorouracil and folinic acid for advanced colorectal cancer in elderly patients: a phase II study. J Clin Gastroenterol 36 (2003) 228-233
29. Mattioli R., Lippe P., Recchia F., et al. Advanced colorectal cancer in elderly patients: tolerance and efficacy of leucovorin and fluorouracil bolus plus continuous infusion. Anticancer Res 21 (2001) 489-492
30. Popescu R., Norman A., Ross P., et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 17 (1999) 2412-2418
31. Haller D., Catalano P., Macdonald J., et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 23 (2005) 8671-8678
32. Gray R., Barnwell J., McConkey C., et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 370 (2007) 2020-2029
33. Capecitabine patient information leaflet. Medmaster patient drug information, American Society of Health System Pharmacists, 2003. Available at http://www.ncbi.nlm.nih.gov/books/bv.fcgi?log$=drug_bottom_one&rid=medmaster.chapter.a699003; accessed March 25, 2008.
34. Twelves C., Wong A., Nowacki M., et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 352 (2005) 2696-2704
35. Poole C., Gardiner J., Twelves C., et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol 49 (2002) 225-234
36. Thom M., Haase N., Rosamond W., et al. Heart disease and stroke Statistics-2006 update: a report from the American Heart Association Statistics Committee and Strokes Statistics Subcommittee. Circulation 113 (2006) 85-151
37. Shah H., Ledbetter L., Diasio R., et al. A retrospective study of coagulation abnormalities in patients receiving concomitant capecitabine and warfarin. Clin Colorectal Cancer 5 (2006) 354-358
38. Yood M., Quesenberry Jr. C., Alford S., et al. An observational study examining the impact of capecitabine on warfarin antithrombotic activity and bleeding complications. Curr Med Res Opin 22 (2006) 307-314
39. Partridge A.H., Archer L.E., Kornblith A.B., et al. CALGB 60104: adherence with adjuvant capecitabine among women age 65 and older with early stage breast cancer treated on CALGB 49907. J Clin Oncol 26 Suppl. l (2008) [abstract 6542]
40. Popa E., Luo W., Hochster H., et al. A phase II study of orzel (UFT + leucovorin) in elderly ≥75 years old) patients with colorectal cancer: results of ECOG 1299. J Clin Oncol 23 16S (2005) [abstract 3608]
41. de Gramont A., Figer A., Seymour M., et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18 (2000) 2938-2947
42. André T., Boni C., Mounedji-Boudiaf L., et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350 (2004) 2343-2351
43. Rothenberg M., Oza A., Bigelow R., et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a Phase III trial. J Clin Oncol 21 (2003) 2059-2069
44. Goldberg R., Sargent D., Morton R., et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22 (2004) 23-30
45. Goldberg R., Tabah-Fisch I., Bleiberg H., et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol 24 (2006) 4085-4091
46. Schmoll H., Tabernero M., Nowacki J., et al. Final safety findings from a randomized phase III trial of capecitabine + oxaliplatin (XELOX) vs. bolus 5-FU/LV as adjuvant therapy for patients (pts) with stage III colon cancer. J Clin Oncol 24 18S (2006) [abstract 3569]
47. Fong Y., Blumgart L., Fortner J., et al. Pancreatic or liver resection for malignancy is safe and effective for the elderly. Ann Surg 222 (1995) 426-434
48. Rees M., Tekkis P., Welsh F., et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247 (2008) 125-135
49. Chau I., Norman A., Cunningham D., et al. Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy. Br J Cancer 91 (2004) 1453-1458
50. Rosati G., and Cordio S. Single-agent irinotecan as second-line weekly chemotherapy in elderly patients with advanced colorectal cancer. Tumori 92 (2006) 290-294
51. Fuchs C., Moore M., Harker G., et al. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer. J Clin Oncol 21 (2003) 807-814
52. Feliu J., Escudero P., Llosa F., et al. Capecitabine as first-line treatment for patients older than 70 years with metastatic colorectal cancer: an Oncopaz Cooperative Group study. J Clin Oncol 23 (2005) 3104-3111
53. Cripps M., Vincent M., Jonker D., et al. Dose reduced first-line capecitabine (Xeloda-TM) monotherapy in older and less fit patients with advanced colorectal cancer. J Clin Oncol 23 16S (2005) [abstract 3577]
54. Saltz L., Cox J., Blanke C., et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343 (2000) 905-914
55. Folprecht G., Seymour M., Saltz L., et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 26 (2008) 1443-1451
56. Souglakos J., Pallis A., Kakolyris S., et al. Combination of irinotecan (CPT-11) plus 5-fluorouracil and leucovorin (FOLFIRI regimen) as first line treatment for elderly patients with metastatic colorectal cancer. A phase II trial. Oncology 69 (2005) 384-390
57. Sastre J., Marcuello E., Masutti B., et al. Irinotecan in combination with fluorouracil in a 48-hour continuous infusion as first-line chemotherapy for elderly patients with metastatic colorectal cancer: A Spanish Cooperative Group for the Treatment of Digestive Tumors study. J Clin Oncol 23 (2005) 3545-3551
58. François E., Berdah J., Chamorey E., et al. Use of the folinic acid/5-fluorouracil/irinotecan (FOLFIRI 1) regimen in elderly patients as a first-line treatment for metastatic colorectal cancer: a Phase II study. Cancer Chemother Pharmacol 62 (2008) 931-936
59. Colucci G., Gebbia V., Paoletti G., et al. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol 23 (2005) 4866-4875
60. Tournigand C., André T., Achille E., et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 22 (2004) 229-237
61. National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Colon Cancer, vol. 1; 2008.
62. Figer A., Perez N., Carola E., et al. 5-Fluorouracil, folinic acid and oxaliplatin (FOLFOX) in very old patients with metastatic colorectal cancer. J Clin Oncol 22 14S (2004) [abstract 3571]
63. Oh D., Kim Y., Han S., et al. Efficacy of reduced dose intensity FOLFOX-4 as first line palliative chemotherapy in elderly patients with advanced colorectal cancer (CRC). J Clin Oncol 24 16S (2005) [abstract 3720]
64. Mattioli R., Massacesi C., Recchia F., et al. High activity and reduced neurotoxicity of bi-fractionated oxaliplatin plus 5-fluorouracil/leucovorin for elderly patients with advanced colorectal cancer. Ann Oncol 16 (2005) 1147-1151
65. Tournigand C., Cervantes A., Figer A., et al. OPTIMOX1: a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer-a GERCOR study. J Clin Oncol 24 (2006) 394-400
66. Figer A., Perez-Staub N., Carola E., et al. FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer: an exploratory cohort of the OPTIMOX1 study. Cancer 110 (2007) 2666-2671
67. Feliu J., Salud A., Escudero P., et al. CAPEOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer. Br J Cancer 94 (2006) 969-975
68. Comella P., Natale D., Farris A., et al. Capecitabine plus oxaliplatin for the first-line treatment of elderly patients with metastatic colorectal carcinoma. Cancer 104 (2005) 282-289
69. Comandone A., Pochettino P., Bergnolo P., et al. Capecitabine and oxaliplatin: a phase II study with a new schedule of administration in elderly patients with advanced colorectal cancer. J Clin Oncol 23 16S (2005) [abstract 3681]
70. Twelves C., Butts C., Cassidy J., et al. Capecitabine/oxaliplatin, a safe and active first-line regimen for older patients with metastatic colorectal cancer: post hoc analysis of a large phase II study. Clin Colorectal Cancer 5 (2005) 101-107
71. Van Cutsem E., Peeters M., Siena S., et al. A phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. J Clin Oncol 25 18S (2007) [abstract 349]
72. Hofheinz R., Kubicka S., Wollert J., et al. Gefitinib in combination with 5-fluorouracil (5-FU)/folinic acid and irinotecan in patients with 5-FU/oxaliplatin-refractory colorectal cancer: a Phase I/II study of the Arbeitsgemeinschaft für Internistische Onkologie (AIO). Onkologie 29 (2006) 563-567
73. Kabbinavar F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 23 (2005) 3697-3705
74. Berry S., Cunningham D., Michael M., et al. Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC-first B.E.A. Trial. J Clin Oncol 24 18S (2006) [abstract 3534]
75. Hedrick E., Kozloff M., Hainsworth J., et al. Safety of bevacizumab plus chemotherapy as first-line treatment of patients with metastatic colorectal cancer: updated results from a large observational registry in the US (BRiTE). J Clin Oncol 24 18S (2006) [abstract 3536]
76. Scappaticci F., Skillings J., Holden S., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 99 (2007) 1232-1299
77. Feliu A, Salut F, Losa M, et al., Bevacizumab plus capecitabine as first-line therapy for advanced or metastatic colorectal cancer in elderly patients-intermediate results. ASCO gastrointestinal cancers symposium; 2008 [abstract 479].
78. Pande A.U., Lombardo J.C., Fakih M., et al. Bevacizumab (BV) induced hypertension (HT): a manageable toxicity. J Clin Oncol 24 Suppl. 18 (2006) [abstract 13539]